Australian non-invasive cardiac monitoring company Uscom Limited (ASX: UCM) today announced the publication of new independent peer reviewed research demonstrating the use of its product as a standard of care for accurate and important cardiac monitoring of critical care patients on ventilators.

The study performed on patients with pneumonia and septic shock admitted to the Intensive Care Unit of Ludwig-Maximilians-University Munich found the USCOM monitor was, “an accurate, easy to use, non-invasive device that detected irregularities in heart function and helped guide medical treatment.”

The results published in Acta Cardiology found, “USCOM constitutes an important tool for easy, rapid and reliable diagnosis and haemodynamic monitoring of critically ill patients.”

The non-invasive cardiac monitoring device has major applications in paediatrics, emergency and intensive care medicine and anesthesia, as well as for management of adult and paediatric sepsis, hypertension, heart failure and for the guidance of cardiovascular fluid and drug therapy.

The study identified the accurate calibration of ventilators as an important clinical application for the patent protected USCOM platform technology, and a new and substantial market.

Uscom Limited Chairman Rob Phillips said, “This study shows ventilators should be calibrated with USCOM. This is more far reaching, practice changing research which at some time will shift the medical monitoring market. Our sector dominating evidence has great value, and our focus is now to develop partnerships with established marketing, distribution and sales organisations which can efficiently and with scale deliver the USCOM technology into multiple revenue opportunities rapidly as practice responds to our mounting evidence.“

“These partnerships will allow us to deliver modular versions of USCOM into portable ultrasound units, monitoring suites, and now into ventilators, as well as continue with stand-alone sales into current and new markets. These licensing partnerships are envisaged to deliver strong profitability to shareholders and be the foundation of the Uscom of the future.”

Ventilation of patients with impaired lung function is an increasingly common treatment in critical care medicine and inappropriate ventilator settings can impair cardiac function, making the patient worse. So an accurate measurement of cardiac output is critical for determining the optimal ventilation settings. Currently cardiac monitoring during ventilation is infrequent because the monitoring methods are invasive and/or inaccurate.

USCOM is approved for use by the US Food & Drug Administration (FDA) and is sold in North America, South America, Europe, the Middle East, Australia, New Zealand, China and South East Asia.

For more information contact: Rob Phillips Executive Chairman Uscom Limited E: rob@uscom.com.au or + 61 2 9247 4144 www.uscom.com.au

References: Horster S, Stemmler HJ, Sparrer J, Tischer T, Hausman A, Geiger S. Mechanical ventilation with positive end-expiratory pressure in critically ill patients: comparison of CW-Doppler ultrasound cardiac output monitoring (USCOM) and thermodilution (PiCCO). Acta Cardiol 2012; 67(2): 177-185, doi: 10.2143/AC.67.2.2154208

Uscom (ASX:UCM)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more Uscom Charts.
Uscom (ASX:UCM)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more Uscom Charts.